No Data
No Data
Medicenna Reports Significant Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response With MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical-stage immunotherapy company focused on the development of
Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee
Medicenna Therapeutics (MDNA.TO) said the American Society of Clinical Oncology (ASCO) has withdrawn its abstract detailing results from the ABILITY-1 monotherapy dose escalation study with MDNA11, in
Medicenna Provides Update on Its Presentations at the 2024 ASCO Annual Meeting
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR
Medicenna Therapeutics Announces Closing of CA$20 Million Investment From RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company")
No Data